News and Updates > Testing results for affected devices
In June 2021, after discovering a potential health risk related to a part in specific CPAP, BiPAP and Mechanical Ventilator devices, Philips issued a voluntary Field Safety Notice (FSN 2021-05-A & FSN 2021-06-A). We continue to work with independent partners to conduct extensive testing and analysis of results on affected devices, including biocompatibility evaluations. Please check this page for updates frequently as we will add new testing results documents as they become available.
We will continue to add up-to-date information within this section as new testing results become available.
16 de mayo de 2023
21 de diciembre de 2022
June 28, 2022
April 25, 2022
July 25, 2022 Philips Respironics engaged external scientific experts to perform an independent systematic literature review of epidemiological studies to evaluate whether use of Continuous or Bilevel Positive Airway Pressure (PAP) devices increases the risk of cancer in obstructive sleep apnea (OSA) patients.
Based on 13 epidemiological studies identified from the systematic literature review, no association has been established between use of PAP devices, including Philips Respironics PAP devices, and risk of cancer in patients with OSA. Two rigorous independent studies showed no statistical difference in cancer risk between OSA patients who used Philips Respironics PAP devices versus other brands of PAP devices. Eleven other epidemiological studies provided little additional insight into this question, but their results generally suggested no excess risk of cancer associated with PAP use for OSA.
You are about to visit a Philips global content page
ContinueSeleccionar país
España (Español)